Abstract
Ovarian cancer is the third most prevalent malignancy of the female reproductive system. Due to its insidious early symptoms, most patients are diagnosed at an advanced stage and have a poor prognosis, highlighting an urgent need for more effective therapeutic strategies. Deltex E3 ubiquitin ligase 3 L (DTX3L), also known as B-lymphoma and BAL-associated protein (BBAP), is an E3 ubiquitin ligase reported to be critical in the progression of various tumors. However, the specific mechanisms underlying the role of DTX3L in ovarian cancer tumorigenesis and progression remain poorly understood. Bioinformatics tools, including GEPIA, GEO, TCGA, Kaplan-Meier Plotter, JASPAR, and STRING, were employed to analyze the expression profiles of DTX3L and 2’-5’-oligoadenylate synthetase 3 (OAS3) in ovarian cancer tissues and normal ovarian tissues, as well as to predict correlations between DTX3L and the JAK1/STAT1/OAS3 signaling axis. At the tissue level, immunohistochemistry (IHC), polymerase chain reaction (PCR), and Western blotting (WB) were conducted to detect the expression of DTX3L and OAS3 in normal ovarian tissues, benign ovarian tumors, borderline ovarian tumors, and ovarian cancer tissues. At the cellular level, ovarian cancer cell lines (A2780, SKOV3, and OVCAR3)assays, CCK-8 assays, wound healing assays, Transwell assays, TUNEL assays, and flow cytometry were performed to assess the effects of altered DTX3L expression on ovarian cancer cell proliferation, migration, invasion, and chemoresistance. Immunofluorescence (IF), PCR, and WB were employed to examine the regulatory effects of DTX3L knockdown or overexpression on OAS3 expression. Additionally, WB was used to evaluate the activation status of the JAK1/STAT1 pathway following manipulation of DTX3L expression. A rescue experiment was conducted to investigate changes in OAS3 expression and the biological behaviors of ovarian cancer cells after simultaneous DTX3L overexpression and inhibition of JAK1 activation. In vivo, nude mouse xenograft models of ovarian cancer with stable DTX3L knockdown or overexpression were established. Tumor growth curves were plotted, and IHC, PCR, and WB were performed to measure DTX3L and OAS3 expression levels in xenograft tumors from each group. DTX3L and OAS3 were highly expressed in ovarian cancer tissues and cell lines. High DTX3L expression promoted proliferation, migration, and invasion of ovarian cancer cells, enhanced resistance to cisplatin, and inhibited apoptosis. Mechanistically, DTX3L upregulated OAS3 expression by activating the JAK1/STAT1 signaling pathway. Inhibition of JAK1/STAT1 signaling partially reversed the oncogenic effects induced by DTX3L overexpression. In vivo experiments showed that DTX3L knockdown suppressed ovarian cancer growth and decreased OAS3 expression in xenograft tumors. DTX3L acts as a potential oncogene in ovarian cancer by inducing OAS3 overexpression via activation of the JAK1/STAT1 signaling pathway, thereby promoting ovarian cancer progression and cisplatin resistance. Collectively, DTX3L holds promise as a biomarker for ovarian cancer diagnosis and prognosis, and represents a novel therapeutic target for ovarian cancer treatment.
Data availability
The data that support the findings of this study are available from the corresponding authors upon reasonable request.
References
Torre, L. A. et al. Ovarian cancer statistics, 2018. CA Cancer J. Clin. 68(4), 284–296 (2018).
Devouassoux-Shisheboran, M. & Genestie, C. Pathobiology of ovarian carcinomas. Chin. J. Cancer. 34 (1), 50–55 (2015).
Seidman, J. D., Yemelyanova, A., Cosin, J. A., Smith, A. & Kurman, R. J. Survival rates for international federation of gynecology and obstetrics stage III ovarian carcinoma by cell type: A study of 262 unselected patients with uniform pathologic review. Int. J. Gynecol. Cancer 22(3), 367–71 (2012).
Zheng, N. & Shabek, N. Ubiquitin ligases: Structure, function, and regulation. Annu. Rev. Biochem. 86, 129–157 (2017).
Spano, D. & Catara, G. Targeting the ubiquitin-proteasome system and recent advances in cancer therapy. Cells 13(1), 29 (2023).
Du, J. et al. A cryptic K48 ubiquitin chain binding site on UCH37 is required for its role in proteasomal degradation. Elife 11, e76100 (2022).
Lauwers, E., Jacob, C. & André, B. K63-linked ubiquitin chains as a specific signal for protein sorting into the multivesicular body pathway. J. Cell. Biol. 185 (3), 493–502 (2009).
Zhao, L. et al. TRAF4-mediated LAMTOR1 ubiquitination promotes mTORC1 activation and inhibits the inflammation-induced colorectal cancer progression. Adv. Sci. (Weinh.) 11(12), e2301164 (2024).
Sun, Y. Targeting E3 ubiquitin ligases for cancer therapy. Cancer Biol Ther 2(6), 623–9 (2003).
Carlos Vela-Rodríguez. Activities and binding partners of E3 ubiquitin ligase DTX3L and its roles in cancer.. Biochem. Soc. Trans. 50 (6), 1683–1692 (2022).
Wang, Lidong. Functions and Molecular Mechanisms of Deltex Family Ubiquitin E3 Ligases in Development and Disease. Front. Cell. Dev. Biol. 25, 9706997 (2021).
Qingsheng, Y. & Ding, J. Khan,et al.DTX3L E3 ligase targets p53 for degradation at poly ADP-ribose polymerase-associated DNA damage.sitesiScience. Iscience 26(4), 17 (2023).
Zhang, Y. et al. PARP9-DTX3L ubiquitin ligase targets host histone H2BJ and viral 3C protease to enhance interferon signaling and control viral infection. Nat. Immunol. 16, 1215–1227 (2015).
Pang-Kuo Lo, Y. et al. LIPG signaling promotes tumor initiation and metastasis of human basal-like triplenegative breast cancer. Elife 19, 7e31334 (2018).
Wei, H. et al. Silencing DTX3L Inhibits the Progression of Cervical Carcinoma by Regulating PI3K/AKT/mTOR Signaling Pathway. Int. J. Mol. Sci(. 3 (1), 861 (2023).
Chen, L. et al. DTX3L Accelerates Pancreatic cancer Progression via FAK/PI3K/AKT Axis. Biochem Genet 17. https://doi.org/10.1007/s10528-023-10451-4 (2023).
Xu, P. et al. DTX3L is upregulated in glioma and is associated with glioma progression. Int. J. Mol. Med. 40 (2), 491–498 (2017).
Johnson, D. P. et al. HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma. Oncotarget 6, 4863–4887 (2015).
Shen, Y. et al. Effects of DTX3L on the cell proliferation, adhesion, and drug resistance of multiple myeloma cells. Tumour Biol 39, 1010428317703941 (2017).
Thang, N. D. et al. Deltex-3-like (DTX3L) stimulates metastasis of melanoma through FAK/PI3K/AKT but not MEK/ERK pathway. Oncotarget 6, 14290–14299 (2015).
Thang, N. D., Minh, N. V. & Huong, P. T. Translocation of BBAP from the cytoplasm to the nucleus reduces the metastatic ability of vemurafenib-resistant SKMEL28 cells. Mol. Med. Rep. 15, 317–322 (2017).
Choi, U. Y., Kang, J. S., Hwang, Y. S. & Kim, Y. J. Oligoadenylate synthase-like (OASL) proteins: dual functions and associations with diseases. Exp. Mol. Med. 47 (3), e144 (2015).
Lin, R. J. et al. Distinct antiviral roles for human 2’,5’-oligoadenylate synthetase family members against dengue virus infection. J. Immunol. 183(12), 8035–43 (2009).
Hu, J. et al. Origin and development of oligoadenylate synthetase immune system. BMC Evol. Biol. 18 (1), 201 (2018).
Koul, A., Hui, L. T., Lubna, N. & McKenna, S. A. Distinct domain organization and diversity of 2’-5’-oligoadenylate synthetases. Biochem. Cell. Biol. 102 (4), 305–318 (2024).
Gao, F., Tan, Y. & Luo, H. MALAT1 is involved in type I IFNs-mediated systemic lupus erythematosus by up-regulating OAS2, OAS3, and OASL. Braz J. Med. Biol. Res. 53 (5), e9292 (2020).
Gao, L. et al. Values of OAS gene family in the expression signature, immune cell infiltration and prognosis of human bladder cancer. BMC Cancer. 22 (1), 1016 (2022).
Zhang, S. et al. Targeting OAS3 for reversing M2d infiltration and restoring anti-tumor immunity in pancreatic cancer. Cancer Immunol. Immunother. 74(1), 37 (2024).
Lu, J., Yang, L., Yang, X., Chen, B. & Liu, Z. Investigating the clinical significance of OAS family genes in breast cancer: An in vitro and in silico study. Hereditas 161(1), 50 (2024).
Ye, Q. et al. DTX3L-mediated TIRR nuclear export and degradation regulates DNA repair pathway choice and PARP inhibitor sensitivity. Nat. Commun. 15 (1), 10596 (2024).
Li, R. et al. Spatial transcriptome profiling identifies DTX3L and BST2 as key biomarkers in esophageal squamous cell carcinoma tumorigenesis. Genome Med. 16 (1), 148 (2024).
Saleh, H., Liloglou, T., Rigden, D. J., Parsons, J. L. & Grundy, G. J. KH-like domains in PARP9/DTX3L and PARP14 coordinate protein-protein interactions to promote cancer cell survival. J. Mol. Biol. 436(4), 168434. https://doi.org/10.1016/j.jmb.2023.168434 (2024).
Bachmann, S. B. et al. DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells. Mol. Cancer 13, 125. https://doi.org/10.1186/1476-4598-13-125 (2014).
Vela-Rodríguez, C. & Lehtiö, L. Activities and binding partners of E3 ubiquitin ligase DTX3L and its roles in cancer. Biochem. Soc. Trans. 50 (6), 1683–1692 (2022).
Scalia, P., Williams, S. J., Suma, A. & Carnevale, V. The DTX protein family: An emerging set of E3 ubiquitin ligases in cancer. Cells 12(13), 1680 (2023).
Xue, C. et al. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal. Transduct. Target. Ther. 8 (1), 204 (2023).
Lockwood, K. C. et al. KIAA0317 regulates SOCS1 stability to ameliorate colonic inflammation. FEBS J. 290(15), 3802–3811 (2023).
Caglar, H. O. et al. Bioinformatics approach combined with experimental verification reveals OAS3 gene implicated in paclitaxel resistance in head and neck cancer. Head Neck 46(9), 2178–2196 (2024).
Zheng, B., Zhou, X., Tian, L., Wang, J. & Zhang, W. IFN-β1b induces OAS3 to inhibit EV71 via IFN-β1b/JAK/STAT1 pathway. Virol. Sin. 37(5), 676–684. https://doi.org/10.1016/j.virs.2022.07.013 (2022).
Funding
The study was supported by the National Natural Science Foundation of China (Project Approval 82260566).
Author information
Authors and Affiliations
Contributions
Fangfang Lu: Writing original draft, Methodology, Investigation.Yang Zhou: Investigation, Data curation. Yi Wei: Investigation, Data curation. Shien Mo: Investigation, Review and editing. Jiajia Tan: Data curation, Review and editing. Yan Kuang: Project administration, Methodology, Supervision.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval
The study protocol has been reviewed and approved by the Ethical Review Committee of the First Affiliated Hospital of Guangxi Medical University(Ethics Approval Number:202508005). Animal experiments were conducted in strict accordance with the guidelines approved by the Animal Care and Welfare Committee of Guangxi Medical University. The tumor burden in nude mice in this study did not exceed the recommended size, and the laboratory animals were anesthetized and euthanized using acceptable methods.Our study was reported in accordance with the ARRIVE guidelines.
Patient consent for publication
All patients who participated in this study have consented to the public publication of this article.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Lu, F., Zhou, Y., Wei, Y. et al. DTX3L promotes ovarian cancer progression and cisplatin resistance by activating JAK1/STAT1/OAS3 pathway. Sci Rep (2026). https://doi.org/10.1038/s41598-026-46935-7
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-026-46935-7
